Action

AKT

Alt Name

Approval Jurisdiction

2023 FDA

Approved for clinical use

HR+ and PI3K mutation breast cancer

Brutto

C₂₁HClN₂₅₆O₂

CAS

1143532-39-1

Compound Image

capivasertib_1.png

Compound name

Capivasertib

InChI

InChI=1S/C21H25ClN6O2/c22-15-3-1-14(2-4-15)17(6-12-29)27-20(30)21(23)7-10-28(11-8-21)19-16-5-9-24-18(16)25-13-26-19/h1-5,9,13,17,29H,6-8,10-12,23H2,(H,27,30)(H,24,25,26)/t17-/m0/s1

InChI Key

JDUBGYFRJFOXQC-KRWDZBQOSA-N

MW

428.90

PubChem CID

25227436

Reference

Reference 2

SMILES

ClC1=CC=C([C@H](CCO)NC(C2(CCN(C3=C4C(NC=C4)=NC=N3)CC2)N)=O)C=C1

Approved Drug List

1